We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Augmented SirT1 Activity Could Protect Against Osteoarthritis

By LabMedica International staff writers
Posted on 07 Dec 2011
Maintaining the activity of the enzyme SirT1 was suggested as a possible new approach to preventing or treating osteoarthritis (OA), a degenerative cartilage disease that affects millions of people around the world.

SirT1 is a histone deacetylase involved in numerous critical cell processes including DNA repair and apoptosis. More...
Previous studies have shown that exposing human osteoarthritic chondrocytes (cartilage cells) to the cytokine TNFalpha generated a stable and enzymatically inactive 75 kDa form of SirT1 (75SirT1) via cathepsin B-mediated cleavage.

Because 75SirT1 was resistant to further degradation, investigators at the Hebrew University of Jerusalem (Israel) assumed it played a distinct role in osteoarthritis (OA) pathology, which they hoped to identify in a study that was published in the October 10, 2011, online edition of the journal Arthritis and Rheumatism.

Over the course of the study OA and normal human chondrocytes were analyzed for the presence of cathepsin B and 75SirT1. Confocal imaging of SirT1 monitored its subcellular trafficking following TNFalpha stimulation.

Results showed that that 75SirT1 was exported to the cytoplasm and colocalized with the mitochondrial membrane. Consistently, immunoprecipitation and immunoblot analyses revealed that 75SirT1 was enriched in mitochondrial extracts and associated with cytochrome C, following TNFalpha stimulation. Preventing nuclear export of 75SirT1 or reducing levels of SirT1 and 75SirT1 augmented chondrocyte apoptosis in the presence of TNFalpha. Cathepsin B and 75SirT1 were elevated in OA as compared to normal chondrocytes. Additional analyses showed that normal human chondrocytes exposed to OA-derived synovial fluid generated the 75SirT1 fragment.

The results indicated that 75SirT1 promoted chondrocyte survival following exposure to proinflammatory cytokines such as TNFalpha. Drug therapies directed at boosting SirT1 production have the potential to retard or reverse OA.

“Developing a combined strategy for diagnosis and treatment, based on these data, could provide an efficient alternative for joint replacement surgery and enable susceptible individuals to experience a better quality of life for years to come,” said senior author Dr. Mona Dvir-Ginzberg, lecturer in the Institute of Dental Sciences at the Hebrew University of Jerusalem.

Related Links:
Hebrew University of Jerusalem



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.